In order to provide the most relevant content to the readers of HealthCare Business News, we're asking you to share a little information about who you are, (it takes two seconds and then you're done).
Register
Edwards Lifesciences puts down $1.2 billion to expand structural heart portfolio
Edwards Lifesciences is making significant investments to enhance its structural heart portfolio through the acquisitions of JenaValve Technology and Endotronix — strategic moves aimed at unmet patient needs in aortic regurgitation (AR) and heart failure (HF), respectively.
The Irvine, California-based company has entered an agreement to acquire JenaValve Technology, which specializes in the transcatheter treatment of aortic regurgitation. Last year, JenaValve reported positive outcomes from its U.S. pivotal trial for treating severe, symptomatic AR in high-risk patients. Edwards anticipates FDA approval for the JenaValve Trilogy Heart Valve System by late 2025, marking it as the first approved therapy for AR patients.
In addition to JenaValve, Edwards has exercised its option to acquire Endotronix, a company focused on heart failure management solutions. Endotronix recently received FDA approval for Cordella, an implantable pulmonary artery pressure sensor designed for early, targeted therapeutic intervention. This acquisition will allow Edwards to extend its structural heart portfolio to include heart failure treatments. The company expects a national coverage determination from CMS for Cordella in early 2025.
“These acquisitions expand our opportunities to address the unmet needs of aortic regurgitation and heart failure patients around the world,” said Bernard Zovighian, Edwards’ CEO. “We are pleased to enter these structural heart therapeutic areas with innovation, world-class science and clinical evidence to provide access to lifesaving technologies for patients around the world.”
The combined upfront purchase price for these acquisitions is approximately $1.2 billion. Edwards expects these investments to solidify its leadership in structural heart innovation and represent long-term growth opportunities. However, the company projects minimal revenue contributions from these acquisitions in 2025. The deals are subject to certain closing conditions, including required antitrust and foreign investment approvals.
